Natalie Iannuzo

Dr. Natalie Iannuzo


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2023 in Cells
Verified
Journal Article
Open access
PDF file
NINatalie Iannuzo
Natalie Iannuzo
ADAlane Blythe Dy
Alane Blythe Dy
SGStefano Guerra
Stefano Guerra
PLPaul R. Langlais
Paul R. Langlais
JLJulie Ledford
Julie Ledford
Club Cell Secretory Protein (CC16) plays many protective roles within the lung; however, the complete biological functions, especially regarding the pulmonary epithelium during infection, remain undefined. We have previously shown that CC16-deficient (CC16−/−) mouse tracheal epithelial cells (MTECs) have enhanced Mp burden compared to CC16-sufficient (WT) MTECs; therefore, in this study, we wanted to further define how the pulmonary epithelium responds to infection in the context of CC16 deficiency. Using mass spectrometry and quantitative proteomics to analyze proteins secreted apically from MTECs grown at an air–liquid interface, we investigated the protective effects that CC16 elicits within the pulmonary epithelium during Mycoplasma pneumoniae (Mp) infection. When challenged with Mp, WT MTECs have an overall reduction in apical protein secretion, whereas CC16−/− MTECs have increased apical protein secretion compared to their unchallenged controls. Following Gene Ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG) assessment, many of the proteins upregulated from CC16−/− MTECS (unchallenged and during Mp infection) were related to airway remodeling, which were not observed by WT MTECs. These findings suggest that CC16 may be important in providing protection within the pulmonary epithelium during respiratory infection with Mp, which is the major causative agent of community-acquired pneumoniae.

9 September 2023 in European Respiratory Journal
Verified
Conference Paper
Closed access
NINatalie Iannuzo
Natalie Iannuzo
HWHolly Welfley
Holly Welfley
NLNicholas Li
Nicholas Li
MJMichael Johnson
Michael Johnson
SGStefano Guerra
Stefano Guerra
JLJulie Ledford
Julie Ledford
Background: CC16 has been shown to protect against the development of obstructive lung diseases and attenuate pulmonary pathogen burden; however, the biological mechanisms of CC16 on pulmonary epithelial responses remain undefined. Methods: Mouse tracheal epithelial cells (MTECS) from CC16 sufficient (WT) and CC16 deficient (CC16-/-) mice were grown at an air-liquid interface and mass spectrometry and quantitative proteomics used to investigate the impact of CC16 on apically secreted proteins. Results: Eight antimicrobials were significantly repressed from CC16-/- MTECs, 6 of which were validated in and human nasal epithelial cells (HNECs). Short Palate Lung and Nasal Epithelial Clone 1 (SPLUNC1) was the most differentially expressed antimicrobial protein (66-fold) and was the focus of this study. We discovered that CC16 enhances epithelial-driven SPLUNC1 production via signaling through the receptor complex Very Late Antigen-2 (VLA-2) and that rCC16 enhances pulmonary SPLUNC1 production in vivo. Conclusions: Our findings identify VLA-2 as a new receptor for CC16 and a novel role of CC16 in the airway epithelium by up-regulating antimicrobials. Clinical Implications: These findings could impact host responses to respiratory pathogens for individuals in which low CC16 levels have been described, including in Asthma, COPD and in Cystic Fibrosis patients.